Other languages Celcuity Inc.

Equities

CELC

US15102K1007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
16.05 ^USD	+0.82%		-8.49%	+10.16%

Mar. 29	Celcuity Inc. Enters into Second Amendment to its Existing Loan and Security Agreement	CI
Mar. 28	Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Celcuity Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Celcuity Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer	Feb. 22
Celcuity Appoints Eldon Mayer as Chief Commercial Officer	Feb. 20
Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium	Dec. 06
Celcuity Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-18
Sector Update: Health Care Stocks Sliding Wednesday Afternoon	23-10-18
Celcuity Launches $50 Million Private Placement; Shares Rise	23-10-18
Celcuity to Proceed With Phase 1b/2 Trial of Gedatolisib Plus Nubeqa, Signs Supply Agreement With Bayer	23-08-22
Celcuity Inc. Announces Plan to Conduct Phase 1B/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer	23-08-22
Celcuity Inc. Enters into Clinical Trial Collaboration and Supply Agreement with Bayer AG to Provide Nubeqa (Darolutamide) for Phase 1B/2 Clinical Trial	23-08-22
Celcuity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Celcuity Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Celcuity Says Phase 1b Gedatolisib Trial With Letrozole, Palbociclib Met Safety and Efficacy Endpoints in Breast Cancer Patients	23-05-12
Celcuity Inc. Announces to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at 2023 ESMO Breast Cancer Annual Congress	23-05-08
Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium	23-02-16
Insider Buy: Celcuity	22-12-13
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer	22-12-07
Celcuity to Present Additional Data for Gedatolisib At the 2022 San Antonio Breast Cancer Symposium	22-11-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Celcuity Inc.

Equities

CELC

US15102K1007

Other languages

Filters